Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension

Safety and Effectiveness of Adcirca (Tadalafil) in Japanese Patients With Pulmonary Arterial Hypertension: Open-label, Non-interventional Observational Study in Japan

To investigate the long-term safety and effectiveness of Adcirca (tadalafil) in Pulmonary Arterial Hypertension (PAH) patients in the clinical practice -focused topics-

1. To evaluate the incidence of adverse events for the patients with long-term use
2. To evaluate the incidence of adverse events of decreased blood pressure, bleeding (including uterine hemorrhage), visual disturbance and sudden hearing loss.

Inclusion Criteria:

• Patients with PAH receiving Adcirca

Exclusion Criteria:Patients who meet the criteria of contraindication

• patients with hypersensitivity to tadalafil
• patients who are using any form of organic nitrate
• patients with severe renal impairment
• patients with severe hepatic impairment
• patients taking strong inhibitors of CYP3A4
• patients taking strong inducers of CYP3A4